The spectrum of multiple sclerosis

Current Allergy and Asthma Reports

Volumn 7, Issue 4, 2007, Pages 280-284

  Heard, Robert N S ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HLA DR ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MYELIN ASSOCIATED GLYCOPROTEIN; PROTEIN NOGO; PROTEIN NOGO A;

CLINICAL FEATURE; DISABILITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; GENETIC SUSCEPTIBILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROPATHOLOGY; ONSET AGE; REVIEW;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS;

EID: 34250786059     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-007-0042-y     Document Type: Review

References (25)

1. Compston A, ed: McAlpine's Multiple Sclerosis, edn 4. New York: Churchill Livingston, 2005.
2. Lublin FD, Reingold SC: Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996, 46:907-911.
3. Weinshenker BG, Bass B, Rice GP, et al.: The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989, 112:133-146.
4. Tullman MJ, Oshinsky RJ, Lublin FD, Cutter GR: Clinical characteristics of progressive relapsing multiple sclerosis. Mult Scler 2004, 10:451-454.
5. Korteweg T, Tintore M, Uitdehaag B, et al.: MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol 2006, 5:221-227.
6. Wilejito M, Shroff M, Buncic JR, et al.: The clinical features, MRI findings and outcome of optic neuritis in children. Neurology 2006, 67:258-262.
7. Tremlett H, Devonshire V: Is late-onset multiple sclerosis associated with a worse outcome? Neurology 2006, 67:954-959.
8. De Stefano N, Cocco E, Lai M, et al.: Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis. Ann Neurol 2006, 59:634-639.
9. Wingerchuk DM, Lennon VA, Pittock SJ, et al.: Revised dignostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
10. Rubio JP, Bahlo M, Butzkueven H, et al.: Genetic dissection of the human leukocyte antigen region by use of haplotypes of Tasmanians with multiple sclerosis. Am J Hum Gen 2002, 70:1125-1137.
11. Lincoln MR, Montpetit A, Cader MZ, et al.: A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005, 37:1108-1112.
12. Giovannoni G, Cutter GR: Infectious causes of multiple sclerosis: contemporary criteria for causation in multiple sclerosis. Lancet Neurol 2006, 5:887-894.
13. Brosnan CF, Raine CS: Mechanisms of immune injury in multiple sclerosis. Brain Pathol 1996, 6:243-257.
14. Barnett MH, Sutton I: The pathology of multiple sclerosis: a paradigm shift. Curr Opin Neurol 2006, 19:242-247.
15. Bruck W, Kuhlmann T, Stadelmann C: Remyelination in multiple sclerosis. J Neurol Sci 2003, 206:181-185.
16. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H: Distinct patterns of multiple sclerosis pathology indicate heterogeneity on pathogenesis. Brain Pathol 1996, 6:259-274.
17. Lucchinetti C, Bruck W, Parisi J, et al.: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707-717.
18. Barnett MH, Prineas JW: Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004, 55:458-468.
19. Lennon VA, Kryzer TJ, Pittock SJ, et al.: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473-477.
20. Weinshenker BG, Wingerchuk DM, Vukusic S, et al.: Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006, 59:566-569.
21. Reindl M, Khalil M, Berger T: Antibodies as biological markers for pathophysiological processes in MS. J Neuroimmunol 2006, 180:50-62.
22. Jurewicz A, Matysiak M, Raine CS, Selmaj K: Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis. Neurology 2007, 68:283-287.
23. Confavreux C, Vukusic S: Natural history of multiple sclerosis: a unifying concept. Brain 2006, 129:606-616.
24. Coles AJ, Wing MG, Molyneux P, et al.: Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999, 46:296-304.
25. Haegert DG: Clinical multiple sclerosis occurs at one end of a spectrum of CNS pathology: a modified threshold liability model leads to new ways of thinking about the cause of clinical multiple sclerosis. Med Hypotheses 2005, 65:232-237.